Briacell Therap Q4 2026 Earnings Results & Report

Briacell Therap EPS Results

• Actual EPS: -$1.50
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A
• EPS Beat Rate: 5 of last 8 quarters

Briacell Therap Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Briacell Therap (NASDAQ:BCTX)eutics Corp. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. Its research is centered on treatments designed to stimulate a patient’s immune system to recognize and attack tumor cells, with an emphasis on advanced breast cancer and other solid tumors.

The company’s lead technology includes Bria-IMT, an off-the-shelf, whole-cell immunotherapy derived from a breast cancer cell line. BriaCell has also been developing Bria-OTS, a personalized immunotherapy approach intended to match treatment with a patient’s human leukocyte antigen profile. Its programs have been evaluated in combination with immune checkpoint inhibitors and other therapies in clinical studies involving patients with metastatic breast cancer.

BriaCell Therapeutics is listed on the Nasdaq Capital Market under the symbol BCTX and on the Toronto Stock Exchange under the symbol BCT. The company is led by William V. Williams, M.D., who serves as president and chief executive officer. Its activities are primarily focused on biotechnology research, clinical development and advancing oncology treatments through regulatory and clinical testing.